Esophageal Cancer
Conditions
Interventions
Patients diagnosed with esophageal cancer and decided to receive chemotherapy or chemoradiotherapy were randomly assigned to the Concomitant use of Prosure group. The basic dose will be set at 2 bottl
Sponsors
Gunma University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients undergoing chemotherapy or chemoradiotherapy for esophageal cancer at Gunma University Hospital (2) Patients of any gender (3) Patients must be at least 20 years of age. (4) Patients who have been fully informed about the participation in this study, fully understand the study, and have given written consent of their own free will.
Exclusion criteria
Exclusion criteria: (1) Patients with diabetes mellitus for whom nutritional supplements are deemed inappropriate (2) Patients who are unable to take oral intake (3) Patients who are judged to be unsuitable for the product by the physician's judgment (4) Patients who are taking EPA preparations (5) Patients who plan to take general medicines or nutritional foods containing high concentrations of EPA or DHA during treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of side effects, progression-free survival, primary tumor shrinkage rate | — |
Countries
Japan
Contacts
Public ContactHideaki Yashima
Gunma University Graduate School of Medicine Department of Clinical Pharmacology and Therapeutics
Outcome results
None listed